Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: A systematic review

Bray, 2012, Global cancer transitions according to the Human Development Index (2008–2030): a population-based study, Lancet Oncol, 13, 790, 10.1016/S1470-2045(12)70211-5 Torre, 2015, Global cancer statistics, 2012, CA Cancer J Clin, 65, 87, 10.3322/caac.21262 Siegel, 2016, Cancer statistics, 2016, CA Cancer J Clin, 66, 7, 10.3322/caac.21332 Howlader, 2017 Del Rio, 2013, Specific extracellular matrix remodeling signature of colon hepatic metastases, PLoS One, 8, 10.1371/journal.pone.0074599 Van Cutsem, 2016, ESMO consensus guidelines for the management of patients with metastatic colorectal cancer, Ann Oncol, 27, 1386, 10.1093/annonc/mdw235 Papamichael, 2015, Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013, Ann Oncol, 26, 463, 10.1093/annonc/mdu253 Talarico, 2004, Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration, J Clin Oncol, 22, 4626, 10.1200/JCO.2004.02.175 Lewis, 2003, Participation of patients 65years of age or older in cancer clinical trials, J Clin Oncol, 21, 1383, 10.1200/JCO.2003.08.010 Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014 Bennouna, 2013, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, Lancet Oncol, 14, 29, 10.1016/S1470-2045(12)70477-1 Bokemeyer, 2011, Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Ann Oncol, 22, 1535, 10.1093/annonc/mdq632 Borner, 2008, Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK, Ann Oncol, 19, 1288, 10.1093/annonc/mdn058 Brodowicz, 2013, FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study, Ann Oncol, 24, 1769, 10.1093/annonc/mdt116 Cassidy, 2011, XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results, Br J Cancer, 105, 58, 10.1038/bjc.2011.201 Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med, 351, 337, 10.1056/NEJMoa033025 Cunningham, 2013, Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial, Lancet Oncol, 14, 1077, 10.1016/S1470-2045(13)70154-2 Diaz-Rubio, 2012, First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study, Oncologist, 17, 15, 10.1634/theoncologist.2011-0249 Dotan, 2012, A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study, J Gastrointest Cancer, 43, 562, 10.1007/s12029-012-9368-3 Douillard, 2014, Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer, Ann Oncol, 25, 1346, 10.1093/annonc/mdu141 Douillard, 2014, FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: the randomized phase II FUTURE study, Clin Colorectal Cancer, 13, 14, 10.1016/j.clcc.2013.11.009 Ducreux, 2013, Eur J Cancer, 49, 1236, 10.1016/j.ejca.2012.12.011 Folprecht, 2014, Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study), Ann Oncol, 25, 1018, 10.1093/annonc/mdu088 Fuchs, 2007, Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study, J Clin Oncol, 25, 4779, 10.1200/JCO.2007.11.3357 Galal, 2008, Role of bevacizumab as post-progression maintenance therapy in metastatic colon cancer, J Med Sci, 8, 452, 10.3923/jms.2008.452.460 Giantonio, 2007, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200, J Clin Oncol, 25, 1539, 10.1200/JCO.2006.09.6305 Grothey, 2013, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 381, 303, 10.1016/S0140-6736(12)61900-X Guan, 2011, Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III artist trial, Chin J Cancer, 30, 682, 10.5732/cjc.011.10188 Hecht, 2009, A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer, J Clin Oncol, 27, 672, 10.1200/JCO.2008.19.8135 Heinemann, 2014, FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial, Lancet Oncol, 15, 1065, 10.1016/S1470-2045(14)70330-4 Hochster, 2008, Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study, J Clin Oncol, 26, 3523, 10.1200/JCO.2007.15.4138 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med, 350, 2335, 10.1056/NEJMoa032691 Hurwitz, 2012, A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard), Oncologist, 17, 937, 10.1634/theoncologist.2012-0071 Jonker, 2007, Cetuximab for the treatment of colorectal cancer, N Engl J Med, 357, 2040, 10.1056/NEJMoa071834 Kabbinavar, 2003, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer, J Clin Oncol, 21, 60, 10.1200/JCO.2003.10.066 Kabbinavar, 2005, Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial, J Clin Oncol, 23, 3697, 10.1200/JCO.2005.05.112 Kato, 2012, Safety verification trials of mFOLFIRI and sequential IRIS+bevacizumab as first- or second-line therapies for metastatic colorectal cancer in Japanese patients, Oncology, 83, 101, 10.1159/000339541 Kemeny, 2011, Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer, J Clin Oncol, 29, 884, 10.1200/JCO.2010.32.5977 Loupakis, 2014, Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer, N Engl J Med, 371, 1609, 10.1056/NEJMoa1403108 Madajewicz, 2012, Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer, Invest New Drugs, 30, 772, 10.1007/s10637-010-9598-9 Maughan, 2011, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial, Lancet, 377, 2103, 10.1016/S0140-6736(11)60613-2 Moosmann, 2011, Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 — a randomized trial of the German AIO CRC study group, J Clin Oncol, 29, 1050, 10.1200/JCO.2010.31.1936 Ocvirk, 2010, Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial, World J Gastroenterol, 16, 3133, 10.3748/wjg.v16.i25.3133 Peeters, 2014, Final results from a randomized phase 3 study of FOLFIRI {+/−} panitumumab for second-line treatment of metastatic colorectal cancer, Ann Oncol, 25, 107, 10.1093/annonc/mdt523 Price, 2014, Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study, Lancet Oncol, 15, 569, 10.1016/S1470-2045(14)70118-4 Primrose, 2014, Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial, Lancet Oncol, 15, 601, 10.1016/S1470-2045(14)70105-6 Saltz, 2012, Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer, Clin Colorectal Cancer, 11, 101, 10.1016/j.clcc.2011.05.006 Saltz, 2007, Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study, J Clin Oncol, 25, 4557, 10.1200/JCO.2007.12.0949 Schmiegel, 2013, Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group, Ann Oncol, 24, 1580, 10.1093/annonc/mdt028 Schwartzberg, 2014, J Clin Oncol, 32, 2240, 10.1200/JCO.2013.53.2473 Seymour, 2013, Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial, Lancet Oncol, 14, 749, 10.1016/S1470-2045(13)70163-3 Sobrero, 2008, EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer, J Clin Oncol, 26, 2311, 10.1200/JCO.2007.13.1193 Souglakos, 2012, Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC), Br J Cancer, 106, 453, 10.1038/bjc.2011.594 Stathopoulos, 2010, Treatment of colorectal cancer with and without bevacizumab: a phase III study, Oncology, 78, 376, 10.1159/000320520 Tebbutt, 2010, Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study, J Clin Oncol, 28, 3191, 10.1200/JCO.2009.27.7723 Tol, 2009, Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer, N Engl J Med, 360, 563, 10.1056/NEJMoa0808268 Tveit, 2012, Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study, J Clin Oncol, 30, 1755, 10.1200/JCO.2011.38.0915 Van Cutsem, 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med, 360, 1408, 10.1056/NEJMoa0805019 Van Cutsem, 2007, Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy — refractory metastatic colorectal cancer, J Clin Oncol, 25, 1658, 10.1200/JCO.2006.08.1620 Van Cutsem, 2012, Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen, J Clin Oncol, 30, 3499, 10.1200/JCO.2012.42.8201 Wasan, 2014, Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial, Lancet Oncol, 15, 631, 10.1016/S1470-2045(14)70106-8 Yalcin, 2013, Bevacizumab+capecitabine as maintenance therapy after initial bevacizumab+XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III “Stop and Go” study results—a Turkish Oncology Group Trial, Oncology, 85, 328, 10.1159/000355914 Yamada, 2013, Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial, Lancet Oncol, 14, 1278, 10.1016/S1470-2045(13)70490-X Ye, 2013, Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases, J Clin Oncol, 31, 1931, 10.1200/JCO.2012.44.8308 Jennens, 2006, Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials, Intern Med J, 36, 216, 10.1111/j.1445-5994.2006.01033.x Fourrier-Réglat, 2014, Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: results of the ETNA cohort, Target Oncol, 9, 311, 10.1007/s11523-013-0296-3 Rouyer, 2016, Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: results of the ETNA observational cohort, J Geriatr Oncol, 7, 187, 10.1016/j.jgo.2016.03.004 Shankaran, 2014, Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer, Oncologist, 19, 892, 10.1634/theoncologist.2013-0209 Tsai, 2013, Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study, Ann Oncol, 24, 1574, 10.1093/annonc/mdt019 Parakh, 2015, Patterns of care and outcomes for elderly patients with metastatic colorectal cancer in Australia, J Geriatr Oncol, 6, 387, 10.1016/j.jgo.2015.06.001 Ward, 2014, Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis, J Geriatr Oncol, 5, 368, 10.1016/j.jgo.2014.05.002 Sorbye, 2009, Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients, Cancer, 115, 4679, 10.1002/cncr.24527 Asmis, 2011, Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care, Ann Oncol, 22, 118, 10.1093/annonc/mdq309 Jackson, 2009, Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study, Cancer, 115, 2617, 10.1002/cncr.24305 Price, 2012, Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C, Ann Oncol, 23, 1531, 10.1093/annonc/mdr488 Aparicio, 2016, Colorectal cancer care in elderly patients: unsolved issues, Dig Liver Dis, 48, 1112, 10.1016/j.dld.2016.05.011 Rosati, 2016, A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer, J Geriatr Oncol, 7, 134, 10.1016/j.jgo.2016.01.006 Sclafani, 2014, Bevacizumab in elderly patients with metastatic colorectal cancer, J Geriatr Oncol, 5, 78, 10.1016/j.jgo.2013.08.006 Tabernero, 2015, Lancet Oncol, 16, 499, 10.1016/S1470-2045(15)70127-0 Tournigand, 2015, Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial, Lancet Oncol, 16, 1493, 10.1016/S1470-2045(15)00216-8 Winther, 2016, Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example, ESMO Open, 1, 10.1136/esmoopen-2015-000021 Seruga, 2016, Under-reporting of harm in clinical trials, Lancet Oncol, 17, e209, 10.1016/S1470-2045(16)00152-2